# JSKN033 in Chinese Subjects with Advanced Malignant Tumors

> **NCT06770881** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 430 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** JSKN033

## Key facts

- **NCT ID:** NCT06770881
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770881, "JSKN033 in Chinese Subjects with Advanced Malignant Tumors". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06770881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*